WHAT IS CLAIMED IS:

1. Use of verinurad or a pharmaceutically acceptable salt thereof, a xanthine oxidase inhibitor, and dapagliflozin in the manufacture of a medicament for a combination therapy for reducing serum uric acid levels in a subject in need thereof, wherein the medicament is to be administered to the subject.
2. Use of verinurad or a pharmaceutically acceptable salt thereof, a xanthine oxidase inhibitor, and dapagliflozin in the manufacture of a medicament for a combination therapy for treating or preventing hyperuricemia in a subject in need thereof, wherein the medicament is to be administered to the subject.
3. Use of verinurad or a pharmaceutically acceptable salt thereof, a xanthine oxidase inhibitor, and dapagliflozin in the manufacture of a medicament for a combination therapy for treating or preventing gout, a recurrent gout attack, gouty arthritis, hypertension, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, chronic kidney disease, kidney stones, kidney failure, diabetic kidney disease, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis, sarcoidosis, hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency or a combination thereof in a subject in need thereof.
4. The use of claim 2, wherein the condition is gout.
5. The use of claim 2, wherein the condition is chronic kidney disease.
6. The use of any one of claims 1 – 5, wherein the xanthine oxidase inhibitor is febuxostat or a pharmaceutically acceptable salt thereof.
7. The use of any one of claims 1 – 5, wherein the xanthine oxidase inhibitor is allopurinol or a pharmaceutically acceptable salt thereof.
8. Use of verinurad or a pharmaceutically acceptable salt thereof, allopurinol or a pharmaceutically acceptable salt thereof, and dapagliflozin in the manufacture of a medicament for a combination therapy for treating or preventing chronic kidney disease in a subject in need thereof, wherein the medicament is to be administered to the subject.
9. Use of verinurad or a pharmaceutically acceptable salt thereof, and a xanthine oxidase inhibitor in the manufacture of a medicament for a combination therapy for reducing serum uric acid levels in a subject who is currently being treated with dapagliflozin, wherein the medicament is to be administered to the subject.

10. The use of claim 9, wherein the subject has diabetes mellitus.

11. The use of claim 9 or 10, wherein the xanthine oxidase inhibitor is febuxostat or a pharmaceutically acceptable salt thereof.

12. The use of claim 9 or 10, wherein the xanthine oxidase inhibitor is allopurinol or a pharmaceutically acceptable salt thereof.

13. Use of verinurad or a pharmaceutically acceptable salt thereof, and a xanthine oxidase inhibitor in the manufacture of a medicament for a combination therapy for treating or preventing hyperuricemia in a subject who is currently being treated with dapagliflozin, wherein the medicament s to be administered to the subject.

14. The use of claim 13, wherein the subject has diabetes mellitus.

15. Use of verinurad or a pharmaceutically acceptable salt thereof, and a xanthine oxidase inhibitor in the manufacture of a medicament for a combination therapy for treating or preventing gout, a recurrent gout attack, gouty arthritis, hypertension, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, chronic kidney disease, kidney stones, kidney failure, diabetic kidney disease, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis, sarcoidosis, hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency or a combination thereof in a subject who is currently being treated with dapagliflozin.

16. Use of verinurad or a pharmaceutically acceptable salt thereof, and a xanthine oxidase inhibitor in the manufacture of a medicament for a combination therapy for treating or preventing gout, a recurrent gout attack, gouty arthritis, hypertension, a cardiovascular disease, coronary heart disease, heart failure, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, chronic kidney disease, kidney stones, kidney failure, diabetic kidney disease, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis, sarcoidosis, hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency or a combination thereof in a subject who is currently being treated with dapagliflozin, wherein the subject has diabetes mellitus.

17. The use of claim 13, wherein the condition is gout.

18. The use of claim 14, wherein the condition is gout.

19. The use of claim 13, wherein the condition is chronic kidney disease.

20. The use of claim 14, wherein the condition is chronic kidney disease.

21. The use of claim 16, wherein the condition is heart failure.

22. The use of any one of claims 13 – 21, wherein the xanthine oxidase inhibitor is febuxostat or a pharmaceutically acceptable salt thereof.

23. The use of any one of claims 13 – 21, wherein the xanthine oxidase inhibitor is allopurinol or a pharmaceutically acceptable salt thereof.

24. Use of verinurad or a pharmaceutically acceptable salt thereof, and allopurinol or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing chronic kidney disease in a subject with diabetes mellitus who is currently being treated with dapagliflozin, wherein the medicament is to be administered to the subject.

25. Use of verinurad or a pharmaceutically acceptable salt thereof, and allopurinol or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing heart failure in a subject with diabetes mellitus who is currently being treated with dapagliflozin, wherein the medicament is to be administered to the subject.

26. A pharmaceutical composition comprising:
verinurad or a pharmaceutically acceptable salt thereof;
a xanthine oxidase inhibitor;
dapagliflozin; and
a pharmaceutically acceptable excipient or carrier.

27. The pharmaceutical composition of claim 26, wherein the xanthine oxidase inhibitor is febuxostat, or a pharmaceutically acceptable salt thereof.

28. The pharmaceutical composition of claim 26, wherein the xanthine oxidase inhibitor is allopurinol, or a pharmaceutically acceptable salt thereof.

29. Use of the pharmaceutical composition of any one of claims 26 – 28 in the manufacture of a medicament for reducing serum uric acid levels in a subject in need thereof, wherein an effective amount of the medicament is to be administered to the subject.

30. Use of the pharmaceutical composition of any one of claims 26 – 28 in the manufacture of a medicament for treating or preventing hyperuricemia in a subject in need thereof, wherein an effective amount of the medicament is to be administered to the subject.

31. Use of the pharmaceutical composition of any one of claims 26 – 28 in the manufacture of a medicament for treating or preventing gout, a recurrent gout attack, gouty arthritis, hypertension, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, chronic kidney disease, kidney stones, kidney failure, diabetic kidney disease, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis, sarcoidosis, hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency or a combination thereof in a subject in need thereof.

32. The use of claim 30, wherein the condition is gout.

33. The use of claim 30, wherein the condition is chronic kidney disease.

.